NI201000056A - Anticuerpos anti-amiloides, composiciones, métodos y usos. - Google Patents

Anticuerpos anti-amiloides, composiciones, métodos y usos.

Info

Publication number
NI201000056A
NI201000056A NI201000056A NI201000056A NI201000056A NI 201000056 A NI201000056 A NI 201000056A NI 201000056 A NI201000056 A NI 201000056A NI 201000056 A NI201000056 A NI 201000056A NI 201000056 A NI201000056 A NI 201000056A
Authority
NI
Nicaragua
Prior art keywords
methods
compositions
amyloid
amyloid antibodies
amyloid antibody
Prior art date
Application number
NI201000056A
Other languages
English (en)
Inventor
S Jung Sun-Yung
Jiang Haiyan
Raghunathan Gopalan
Borozdina-Birch Lionella
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NI201000056A publication Critical patent/NI201000056A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

La presente invención se relaciona a un anticuerpo humano anti-amiloide, que incluye ácidos nucleicos aislados que codifican el anticuerpo anti-amiloide, amiloides, vectores, células hospederas, animales o plantas transgénicos, y métodos para preparar y usar los mismos, incluyendo composiciones, métodos y dispositivos terapéuticos.
NI201000056A 2007-10-15 2010-04-14 Anticuerpos anti-amiloides, composiciones, métodos y usos. NI201000056A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97995407P 2007-10-15 2007-10-15

Publications (1)

Publication Number Publication Date
NI201000056A true NI201000056A (es) 2010-11-10

Family

ID=40568052

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000056A NI201000056A (es) 2007-10-15 2010-04-14 Anticuerpos anti-amiloides, composiciones, métodos y usos.

Country Status (16)

Country Link
US (1) US20100074901A1 (es)
EP (1) EP2211886A4 (es)
JP (1) JP2011500059A (es)
KR (1) KR20100075639A (es)
CN (1) CN102762220A (es)
AU (1) AU2008312611A1 (es)
CA (1) CA2703050A1 (es)
CO (1) CO6270335A2 (es)
CR (1) CR11434A (es)
EA (1) EA201070479A1 (es)
IL (1) IL204930A0 (es)
MX (1) MX2010004179A (es)
NI (1) NI201000056A (es)
SV (1) SV2010003533A (es)
WO (1) WO2009052125A2 (es)
ZA (1) ZA201003427B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101140934B1 (ko) 2010-08-05 2012-05-03 삼성전기주식회사 초음파 영상의 음속도 추정 방법 및 이를 적용한 초음파 진단 장치
EP2672995B1 (en) 2011-02-11 2019-01-02 Research Corporation Technologies, Inc. Ch2 domain template molecules derived from rational grafting of donor loops onto ch2 scaffolds
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
BR112013023211B1 (pt) * 2011-03-16 2022-11-08 Vivoryon Therapeutics N.V. Anticorpo monoclonal, seu uso, composição, linhagem celular, método diagnóstico in vitro e kit
ES2762806T3 (es) 2014-02-10 2020-05-25 Respivant Sciences Gmbh Tratamiento utilizando estabilizadores de mastocitos para trastornos sistémicos
CA2938996A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the treatment of lung diseases with mast cell stabilizers
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
CN106344931A (zh) * 2016-08-29 2017-01-25 苏州普罗达生物科技有限公司 一种小分子淀粉样蛋白抗体多肽与雌激素的偶联结合物
EP3506893A4 (en) 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYNE COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS
JP2019531308A (ja) 2016-10-07 2019-10-31 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 肺線維症の治療のためのクロモリン組成物
GB201701404D0 (en) * 2017-01-27 2017-03-15 Micropharm Ltd Therapies for treating inflammatory disorders
EP3628009A4 (en) * 2017-05-19 2021-03-24 The Regents of The University of Colorado, A Body Corporate COMPOSITIONS AND PROCESSES FOR IMPROVING PERCEPTION
CN108704125A (zh) * 2018-06-20 2018-10-26 深圳大学 一种治疗二型糖尿病的疫苗、制备方法及应用
CN110511276A (zh) * 2019-08-13 2019-11-29 王跃驹 植物作为宿主在表达Aducanumab抗体中的应用
KR20220087439A (ko) * 2019-09-10 2022-06-24 에이씨 이뮨 에스에이 진단을 위한 신규 분자
WO2021113899A1 (en) * 2019-12-11 2021-06-17 Ambetex Pty Ltd Therapeutic compositions comprising an amyloid beta antibody or vaccine for prevention and treatment of diastolic dysfunction
CN113138276B (zh) * 2020-01-19 2022-09-16 厦门万泰凯瑞生物技术有限公司 用于检测HBcAg的方法及抗体
CN113178001B (zh) * 2021-04-01 2023-07-04 北京科技大学 面向孔源性视网膜脱离的硅油填充模拟方法及电子设备

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
KR20060054174A (ko) * 2003-03-28 2006-05-22 센토코 인코포레이티드 항-아밀로이드 항체, 조성물, 방법 및 용도
US7807165B2 (en) * 2004-07-30 2010-10-05 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
US20060246075A1 (en) * 2004-09-29 2006-11-02 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses

Also Published As

Publication number Publication date
SV2010003533A (es) 2011-01-10
CR11434A (es) 2011-01-14
EA201070479A1 (ru) 2010-12-30
ZA201003427B (en) 2011-10-26
IL204930A0 (en) 2010-11-30
US20100074901A1 (en) 2010-03-25
KR20100075639A (ko) 2010-07-02
CO6270335A2 (es) 2011-04-20
MX2010004179A (es) 2010-08-04
CA2703050A1 (en) 2009-04-23
WO2009052125A9 (en) 2010-02-11
AU2008312611A1 (en) 2009-04-23
WO2009052125A2 (en) 2009-04-23
EP2211886A2 (en) 2010-08-04
CN102762220A (zh) 2012-10-31
JP2011500059A (ja) 2011-01-06
EP2211886A4 (en) 2011-07-27

Similar Documents

Publication Publication Date Title
NI201000056A (es) Anticuerpos anti-amiloides, composiciones, métodos y usos.
CR9606A (es) Anticuerpos anti-proteina quinoatrayente de monocitos-1, composiciones, metodos y usos
AR053370A1 (es) Anticuerpos anti-il-6 composiciones , metodos y usos
UY30494A1 (es) Mimeticuerpos de glp-1 humanos, composiciones, métodos y usos
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
UY29128A1 (es) Proteinas derivadas de inmunoglobulina específica de il-23p40, composiciones, epitopes, métodos y usos
CO6351748A2 (es) Anticuerpos contra il-6 y sus usos
CR20130016A (es) ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
EA200501524A1 (ru) Антитела против амилоида, композиции, способы и применения
CO6602147A2 (es) Uso de combinado de proteínas cry1ca y cry1fa para el manejo de la resistencia de insectos
UY31361A1 (es) Vacunas y componentes para inhibir celulas microbianas
UY32971A (es) Proteínas de unión al antígeno de la il-23 humana
CO6602149A2 (es) Uso combinado de vip3ab y cry1fa para el manejo de insectos resistentes
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
EA200601603A1 (ru) Миметические антитела glp-1 человека, композиции, способы и применения
CL2008001682A1 (es) Metodos para el mejoramiento de plantas mediante el uso de informacion directa de secuencias de acidos nucleicos.
CO6602146A2 (es) Uso combinado de proteínas cryda y cry1fa para el manejo de la resistencia de los insectos
AR073088A1 (es) Anticuerpos anti-il-13 obtenidos mediante ingenieria composiciones metodos y usos
UY30820A1 (es) Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
MX2014012977A (es) Anticuerpos anti-cd22.
BR112013005136A2 (pt) composições e métodos para controlar pragas de nematodeo
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
AR079505A1 (es) Uso de cry1da en combinacion con cry1ca para el manejo de insectos resistentes
CR9481A (es) Mimeticuerpos de peptido similar a glucagon-1 humanos, composiciones, metodos y usos
UY29509A1 (es) Anticuerpos anti-il-6, composiciones, métodos y usos